Returning to Boston this December, the 3rd Gene Therapy for Neurological Disorders meeting will welcome discovery, preclinical, translational and clinical industry scientists to share, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS.
With 40+ expert leaders from the likes of Taysha Gene Therapies, Passage Bio, AskBio, Neurogene, Affinia Therapeutics and Alycone Therapeutics sharing their progress, don't miss the chance to join the industry's definitive physical conference to make new connections and reconnect with your friends and colleagues.
Over 4 comprehensive days of networking, presentations and discussion sessions, the 3rd Gene Therapy for Neurological Disorders meeting will enable you to:
- Discuss the latest DRG toxicity and immunogenicity research to understand the biology behind AAV toxicity in the CNS
- Evaluate current safety and toxicity strategies to navigate off target effects including redosing options
- Evaluate intraparenchymal, intra-cisterna magna, lumbar intrathecal and systemic delivery routes for CNS indications to assess CNS tropism and biodistribution
- Hear from neurosurgeons at the forefront of delivery and explore the most up to date delivery devices to identify novel innovations and areas for development
- Review pharmacological concepts for preclinical dose selection in NHP biodistribution case studies to optimize dose extrapolation
- Learn about the different vector discovery strategies used to identify vectors with improved CNS tropism and specificity
- Optimize clinical trial design considerations for both paediatric and adult neurological patient populations to showcase efficacy to regulators and deliver value for patients
- Discover the novel indications being targeted by gene therapies such as epilepsy, neuropathic pain and hearing disorders to improve your knowledge of current CNS pipelines
Visit our website to access your copy of the event guide containing the full agenda, speaker list and pricing and discounts: www.genetherapy-neurological.com
Full Access Pass - Physical - Standard Rate: USD 3593.00,
Conference + Workshop Day OR Post Event Delivery Day - Physical - Standard Rate: USD 2846.00,
Conference Only - Physical - Standard Rate: USD 2099.00
Speakers: Alan Foster, Chief Scientific Officer, Otonomy, Inc., Alexandra Watt, Lead Research Analyst, Beacon Targeted Therapies, Amanda Haidet-Philips, Senior Director, Translational Medicine and Ultra-Rare Diseases, Novartis Gene Therapies, Amber Van Laar, Vice President, Clinical Development, AskBio, Andrea Campanile, Vice President, Clinical Operations, Passage Bio, Brian Fiske, Co-Chief Scientific Officer, The Michael J Fox Foundation, Bryn Martin, Vice President, Research, Precision Delivery, and CSF Sciences, Alcyone Therapeutics, Charles Albright, Chief Scientific Officer, Affinia Therapeutics, Chris Tarapata, Head, Implantable and Specialized Devices, Takeda, Eliseo Salinas, Chief R&D Officer, Passage Bio, Eric Kelsic, Founder and Chief Executive Officer, Dyno Therapeutics, Federico Mingozzi, Chief Scientific Officer, Spark Therapeutics, Gavin Corcoran, Chief Research and Development Officer, Sio Gene Therapies, Gregory LaRosa, Vice President, Head of Scientific Research and Development, Rare Disease RU, Pfizer, Gregory Stewart, Executive Vice President, Research and Development, Alcyone Therapeutics, Hatim Zariwala, Associate Director, Neuroscience, Voyager Therapeutics, Henrik Zetterberg, Professor of Neurochemistry, University of Gothenburg, Sweden; University College London, Heather Gray-Edwards, Assistant Professor, Department of Radiology, Horae Gene Therapy Center, University of Massachusetts Medical School, Jennifer Daily, Executive Director, Preclinical Development, Neurogene, John Shoffner, Vice President, Head of CNS Therapeutics, Clinical Sciences, Sangamo Therapeutics, Juliette Hordeaux, Senior Director, Translational Research and Lysosomal Storage Disease, University of Pennsylvania, Junghae Suh, Vice President, Gene Therapy Accelerator Unit, Biogen, Karen Kozarsky, Founder and Chief Scientific Officer, SwanBio, Krystof Bankiewicz, Professor of Neurosurgery and Director Brain Health and Performance Center, The Ohio State University; AskBio, Larry Whiteley, Pathology and Investigative Toxicology Scientific and Strategic Advisor, Pfizer, Li Chin, Wong Director, Bioanalytical and Biomarker Development, Prevail Therapeutics, Marie-Laure Nevoret, Senior Clinical Development Lead, REGENXBIO, Mark Tuszynski, Professor and Director, Translational Neuroscience Institute, UC San Diego School of Medicine, Martin Marsala, Professor, Department of Anesthesiology, UC San Diego School of Medicine, Mathew Pletcher, Senior Vice President, Gene Therapy, Astellas, Melissa Kotterman, Vice President, Head of Discovery and Engineering, 4D Molecular Therapeutics, Michelle Krishnan, Senior Medical Director, Novartis Gene Therapies, Monica Bennett, Head of Gene Therapy Unit, Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Nathalie Cartier, CNS, AskBio, Paul Larson, Professor and Vice Chair of Neurological Surgery, The University of California San Francisco, Petra Kaufmann, Chief Medical Officer, Affinia Therapeutics, Ronald Crystal, Founder and Chief Scientific Adviser, Lexeo Therapeutics, Salvador Rico, Chief Scientific Officer, Encoded Therapeutics, Sergey Aksenov, Senior Director, Preclinical and Early Development Pharmacometrics, Novartis Institutes for BioMedical Research (NIBR), Sue Browne, Vice President, Research, Passage Bio, Suyash Prasad, Chief Medical Officer and Head of Research and Development, Taysha Gene Therapies, Steven Gray, Associate Professor, University of Texas Southwestern Medical Center; Chief Scientific Adviser, Taysha Gene Therapies, Tippi MacKenzie, Professor, Surgery; Co-Director, Center for Maternal-Fetal Precision Medicine, University of California, San Francisco, Fernando Aleman, Chief Scientific Officer, Navega Therapeutics